MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)

https://www.morphosys.com

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, MOR208, has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 320 employees. *

	Start	1992-01-01 established
	Group	MorphoSys (Group)
	Predecessor	MorphoSys GmbH
	Industry	biopharmaceutical
	Person	Kress, Jean-Paul (MorphoSys 201909– CEO before Syntimmune + Biogen + Sanofi Genzyme)
	Person 2	Lee, Sung (MorphoSys 202102–202303 CFO before Sangamo + Gilead Sciences LEFT 3/23)

	Region	Martinsried
	Country	Germany
	Street	7 Semmelweisstr.
	City	82152 Planegg
	Tel	+49-89-89927-0
		Address record changed: 2022-09-17

Basic data	Employees	E: 501 to 1,000 (2022-12-31)
	Currency	EUR
	Annual sales	278,267,003 (revenues, consolidated (2022) 2022-12-31)
	Profit	-151,058,190 (2022-12-31)
	Cash	402,350,904 (2022-12-31)

		* Document for »About Section«: MorphoSys AG. (1/31/19). "Press Release: MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab". Planegg.

		Record changed: 2023-07-10